Phase II Study of Targeting CD28 in Multiple Myeloma With Abatacept (CTLA4-Ig) to Overcome Resistance to Chemotherapy
Phase of Trial: Phase II
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Abatacept (Primary) ; Abatacept (Primary) ; Dexamethasone (Primary) ; Ixazomib (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 02 Dec 2019 Planned End Date changed from 8 Nov 2020 to 25 Jun 2021.
- 02 Dec 2019 Planned primary completion date changed from 8 Nov 2019 to 25 Jun 2020.
- 31 Aug 2018 Biomarkers information updated